- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05412082
SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer (SMART TNT)
Selective Treatment With Magnetic Resonance Image Guided Pelvic Adaptive Radiation Therapy Combined With Total Neoadjuvant ChemoTherapy for the Conservative Management of Locally Advanced Rectal Cancer
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Zuzel Rodriguez
- Phone Number: 305-243-0124
- Email: z.rodriguez1@med.miami.edu
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami
-
Contact:
- Zuzel Rodriguez
- Phone Number: 305-243-0124
- Email: z.rodriguez1@med.miami.edu
-
Contact:
- Lorraine Portelance, MD
- Phone Number: 305-243-4200
- Email: lportelance@med.miami.edu
-
Principal Investigator:
- Lorraine Portelance, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with newly diagnosed, biopsy proven, rectal adenocarcinoma.
- Primary tumor located ≤18 cm from margin verge.
- Primary tumor either a T3N0 or T1-4 N positive (as defined per pelvic MRI; nodes ≤ 15 mm).
- ≥ 18 years of age.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Serum liver function tests values within the range of 1.5 x Upper Limit of Normal (within 6 weeks of enrollment).
- Negative pregnancy test for women of child-bearing potential (within 4 weeks of enrollment).
- Ability to understand and the willingness to sign a written informed consent document.
- Patient is assessed by a surgeon, medical oncologist and a radiation oncologist and deemed fit for Total Neoadjuvant ChemoTherapy (TNT) and surgery.
Exclusion Criteria:
- Metastatic disease on initial work up (Chest and abdomen contrast enhanced CT scan).
- Synchronous lesion found on colonoscopy.
- Previous history of pelvic radiotherapy.
- History of concurrent, active malignancy, other than non metastatic skin cancer within the last 5 years.
- Symptomatic congestive heart failure of New York Heart Association Class III or IV, unstable angina pectoris or serious uncontrolled cardiac arrhythmia, myocardial infarction within the last 6 months.
- Psychiatric illness/social situations that would limit compliance with study requirements.
- Active (acute or chronic) or uncontrolled severe infections requiring intravenous antibiotics or active tuberculosis (TB).
- Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition or known HIV seropositivity; note, however, HIV testing is not required for entry into this protocol. The need to exclude patients with HIV/AIDS from this protocol is based on the fact that the treatments involved in this protocol may be significantly immunosuppressive.
- Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity
- Sensory or motor neuropathy ≥ grade 2.
- Women who are breast feeding.
- Exclusions due to MRI use in study: ferromagnetic metal in body/eye, pacemaker, defibrillator, other mechanical device, or extreme claustrophobia (medication with anti-anxiety agents, such as Ativan, may be attempted).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SMART TNT Plan I
Participants will initiate therapy with neoadjuvant chemotherapy of either six (6) 14-day cycles of 5-fluorouracil + leucovorin + oxaliplatin (FOLFOX) or four (4) 21-day cycles of capecitabine+oxaliplatin (CAPOX). Participants will then receive chemo-radiation therapy according to Plan I as follows: Plan I (5 weeks):
After completing Plan I, participants achieving complete Clinical Response (cCR) after completing Plan I chemo-radiation will forgo the Plan II boost and continue to follow-up. Participants not achieving cCR will begin Plan II, one week after completing Plan I. |
MRI-guided pelvic IMRT to the Planning Tumor Volume (PTV) at a dose of 50 Grays (gy) delivered in 25 fractions (fx) over 5 weeks.
Other Names:
5-FU dose of 400 mg/m2 will be administered intravenously (IV) over 5-15 minutes beginning on Day 1; then a dose of 2400 mg/m2 via continual infusion (CI) over 4446-478 hours total dose during Days 1 and 2 of every 14-day cycle, for 4 to 6 cycles. During SMART TNT Plan I, 5-FU dose of 225 mg/m2 per day will be administered via CI on Day 1 radiation therapy, delivered either 5 or 7 days per week.
Other Names:
Leucovorin dose of 400 mg/m2 bolus will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
Other Names:
Oxaliplatin dose of 85 mg/m2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 - 6 cycles.
Other Names:
Capecitabine will be administered orally at a dose of 825 mg/m2 via tablet twice per day (BID) on Day 1, 5 days per week.
Other Names:
|
Experimental: SMART TNT Plan II
Plan II boost RT (1 week): For participants not achieving cCR after chemo-radiation. Participants will receive MRI-guided accelerated radiation therapy (ART) boost to the primary tumor. Participants achieving a cCR will continue to follow-up. Participants still showing residual tumor will undergo standard of care treatment including surgery and adjuvant chemotherapy per institutional guidelines during follow-up. |
MRI-guided Pelvic accelerated radiation therapy (ART) given over one week at one of the following dose levels :
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Toxicity Among Participants After Start Receiving MRI-g Pelvic ART
Time Frame: Up to 30 months
|
Reported as the incidence of toxicity (adverse events and serious adverse events) in study participants after start of MRI-g Pelvic ART.
Toxicity in study participants will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, per physician discretion.
|
Up to 30 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Acute and Long-Term Toxicity After Start of Study Therapy
Time Frame: Up to 30 months
|
Reported as the incidence of grade 3 or higher acute and long-term toxicity by organ in study participants after start of study therapy.
These toxicities will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, per physician discretion.
|
Up to 30 months
|
Percentage of Participants with Documented Local Control
Time Frame: Up to 2 years
|
Local control is defined as the stopping of cancer growth at the original primary site.
The percentage of participants with documented local control after study therapy will be reported.
|
Up to 2 years
|
Percentage of Participants with Documented Distant Metastasis
Time Frame: Up to 2 years
|
Distant metastasis is defined as cancer that has spread form the original (primary) tumor to distant organs and distant lymph nodes.
The percentage of participants with documented distant metastasis after study therapy will be reported.
|
Up to 2 years
|
Disease-free Survival (DFS) rate
Time Frame: Up to 2 years
|
Disease-free survival is defined as the elapsed time after treatment that a person with disease lives without known disease recurrence.
DFS rate will be reported as the percentage of participants without disease recurrence after start of treatment.
|
Up to 2 years
|
Overall Survival (OS)
Time Frame: Up to 2 years
|
OS will be reported as the number of participants still alive after start of treatment.
|
Up to 2 years
|
Percentage of Real Negatives
Time Frame: Up to 6 months
|
The sensitivity and specificity of multiparametric magnetic resonance imaging (mpMRI) to measure tumor response will be reported as the percentage of real negatives during the course of treatment of study participants.
|
Up to 6 months
|
Health-related Quality of Life (HRQOL) Scores: Patient-Reported Outcomes Measurement Information System (PROMIS)
Time Frame: Up to 30 months
|
Patient-Reported Outcomes (PRO) will be measured using the 29-item NIH PROMIS questionnaire, a validated HRQOL measure that provides global levels of health-related quality of life.
PROMIS has subscales of emotional distress, fatigue, pain, physical function, sleep disturbance, and satisfaction with social participation.
|
Up to 30 months
|
Health-related Quality of Life (HRQOL) Scores: Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Up to 30 months
|
Health-related quality of life will be reported using Pittsburgh Sleep Quality Index (PSQI) which assesses patient-reported sleep quality over a 1-month time interval.
The PSQI consists of 19 items including 7 sleep components (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction) that produce one global score.
Each item is weighted on a 0-3 interval scale.
The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality.
|
Up to 30 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lorraine Portelance, MD, University of Miami
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Rectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protective Agents
- Micronutrients
- Vitamins
- Antidotes
- Vitamin B Complex
- Fluorouracil
- Capecitabine
- Oxaliplatin
- Leucovorin
Other Study ID Numbers
- 20210172
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Rectal Cancer
-
Fondazione Policlinico Universitario Agostino Gemelli...Viewray Inc.UnknownLocally Advanced Rectal Cancer | Pathological Complete Response | Neoadjuvant ChemoradiotherapyItaly
-
University Hospital Southampton NHS Foundation...Cancer Research UK; IntraOp Medical Corporation; PLANETS Cancer CharityRecruitingLocally Advanced Rectal Cancer | Locally Recurrent Rectal CancerUnited Kingdom
-
St Vincent's University Hospital, IrelandRecruitingLocally Advanced Rectal Cancer | Pelvic Exenteration | Advanced Pelvic MalignancyIreland
-
Beijing Friendship HospitalChanghai Hospital; Peking Union Medical College Hospital; Peking University Cancer...Not yet recruitingLocally Advanced Rectal CancerChina
-
Sun Yat-sen UniversityAkeso; Haplox Biotechnology Co., Ltd.RecruitingLocally Advanced Rectal CancerChina
-
Peking Union Medical College HospitalNot yet recruitingLocally Advanced Rectal Cancer
-
Beijing Friendship HospitalPeking University First Hospital; Peking University People's Hospital; Peking... and other collaboratorsRecruitingLocally Advanced Rectal CancerChina
-
Zhejiang Cancer HospitalRecruiting
-
Fundación para el Fomento de la Investigación Sanitaria...Hospital General Universitario ElcheRecruiting
-
Gruppo Oncologico del Nord-OvestActive, not recruitingLocally Advanced Rectal CancerItaly
Clinical Trials on Intensity-modulated radiation therapy
-
National Cancer Institute (NCI)TerminatedLocally Recurrent Head and Neck Squamous Cell Carcinoma | Nasopharyngeal Squamous Cell Carcinoma | Sinonasal Squamous Cell CarcinomaUnited States
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Prostate AdenocarcinomaUnited States, Canada, Hong Kong, Switzerland, India, Ireland
-
Mount Sinai Hospital, CanadaPrincess Margaret Hospital, CanadaActive, not recruitingAdult Soft Tissue SarcomaCanada, United States, Belgium
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck CarcinomaUnited States
-
Institut Cancerologie de l'OuestCompletedCervical Cancer | Prostate Cancer | Anal Canal CancersFrance
-
Memorial Sloan Kettering Cancer CenterCompletedMetastatic DiseaseUnited States
-
University Health Network, TorontoOntario Cancer Research NetworkCompleted
-
Xiangya Hospital of Central South UniversityRecruitingNasopharyngeal CarcinomaChina
-
Alberta Health servicesCompleted
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditionsUnited States